Table 2.

Baseline of participants of the included studies.

	Daridorexant 50 mg (n = 429)	Daridorexant 25 mg (n = 737)	Daridorexant 10 mg (n = 423)	Daridorexant 5 mg (n = 118)	Placebo (n = 736)
Sex
Female	277	511	292	77	492
Male	152	226	131	41	244
Age	55.8	56.3	57.1	55.5	56.1
Race
White	384	668	376	108	651
Black or African American	38	52	27	8	67
Asian	4	14	14	0	13
Other	3	3	6	2	5
Body-mass index, kg/m2	26.0	26.2	25.9	25.3	26.2
Nighttime efficacy variables
WASO, min	98*	102.8†	105.5‡	106.7§	105.4∥
LPS, min	65.8*	69.3†	68.1‡	74.2§	69.9∥
Self-reported total sleep time, min	311.9*	309.3†	307.4‡	309.8§	311.9∥
Total sleep time, min	312.7*	315.5†	314.4‡	306.8§	312.1∥
Insomnia Severity Index score	19.7	19.5	20.2	20.7	19.6

LPS = latency to persistent sleep, WASO = wake time after sleep onset.

^*n = 427.

^†n = 734.

^‡n = 419.

^§n = 116.

^∥n = 732.